Michael A. Postow

Michael Postow practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Michael Postow's NPI, 1487853594, was assigned on July 18, 2007. Michael Postow graduated from New York University School of Medicine in 2007. Michael Postow's Massachusetts license number on file is 232384.

Michael Postow's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Michael Postow's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Michael Postow is also affiliated with Brigham and Women's Hospital. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Michael Postow to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Postow practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Michael Postow's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Michael Postow is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Michael Postow's licenses on file in 5 states: Massachusetts, Florida, New Jersey, New York and Connecticut.

Dmand AI lists colorectal cancer, lymphoma and prostate cancer among the conditions Michael Postow treats.

CMS data shows 701 Medicare services from Michael Postow across 6 procedure codes in 2024, for 236 Medicare patients. Medicare paid $63,614 for them.

CMS counts 236 Medicare patients who saw Michael Postow in 2024. The largest group is 75 to 84, with 100 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michael Postow's median patient age at 73, with 37% women.

In 2024, Michael Postow wrote 268 Medicare Part D claims for 58 patients. 62% of them were for generic drugs. CMS names the drug for 149 of them, across 5 drugs with 11 or more claims each, at $772,803 in total drug cost. In 2023, CMS named 82 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Michael Postow for performance year 2024, reported as part of a group. Michael Postow accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Michael Postow as offering telehealth.

Dmand AI links 165 papers to Michael Postow, published from 2012 to 2025. 2017 was the busiest year, with 17. The most frequent topics are Melanoma, Ipilimumab and Skin Neoplasms. Michael Postow has published most often in J Clin Oncol. Michael Postow's most frequent co-authors are Jedd D. Wolchok, MD, Alexander Noor Shoushtari, MD and Paul B. Chapman, MD.

Dmand AI links Michael Postow to 2 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Melanoma and Nevi and Melanomas. Memorial Sloan Kettering Cancer Center sponsors the most, 2.

CMS Open Payments shows 148 general payments to Michael Postow from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Bristol-Myers Squibb Company paid the most, $86,811. It also lists 4 research payments totaling $7,280 from 2021 to 2024.

Michael Postow graduated from New York University School of Medicine in 2007.

Michael Postow is in network with 9 carriers, including Excellus BlueCross BlueShield, United Healthcare and HCSC. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.